Trial Profile
Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine When Given as a Booster Dose
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 22 Jan 2009 Planned number of patients changed from 386 to 219 as reported by ClinicalTrials.gov.
- 22 Jan 2009 Planned number of patients changed from 386 to 219 as reported by ClinicalTrials.gov.
- 22 Jan 2009 Additional locations identified as reported by ClinicalTrials.gov, last updated 22 Jan 2009.